EANO-ESMO Guidelines for Brain
Metastasis Management Questions
And Answers
/.What do the EANOeESMO Clinical Practice Guidelines focus on? - Answer-
✅Diagnosis, treatment, and follow-up of patients with brain metastasis from solid
tumors.
/.Who are the authors of the EANOeESMO Clinical Practice Guidelines? - Answer-✅E.
Le Rhun, M. Guckenberger, M. Smits, R. Dummer, T. Bachelot, F. Sahm, N. Galldiks,
E. de Azambuja, A. S. Berghoff, P. Metellus, S. Peters, Y.-K. Hong, F. Winkler, D.
Schadendorf, M. van den Bent, J. Seoane, R. Stahel, G. Minniti, P. Wesseling, M.
Weller, and M. Preusser.
/.What is the significance of the EANOeESMO recommendations despite the low level
of evidence? - Answer-✅They serve as a valuable source of information for physicians,
healthcare providers, and informed patients and relatives.
/.What is the basis for the recommendations in the EANOeESMO guidelines? - Answer-
✅The recommendations are often based on expert opinion and consensus rather than
on evidence from informative clinical trials.
/.What are some key terms associated with the EANOeESMO guidelines? - Answer-
✅Central nervous system, cerebral, clinical practice, guideline, neurological,
recommendations.
/.When were the EANOeESMO Clinical Practice Guidelines made available online? -
Answer-✅6 August 2021.
/.What is the role of the EANO Executive Board and ESMO Guidelines Committee in the
guidelines? - Answer-✅They are responsible for the development and endorsement of
the clinical practice guidelines.
/.What types of care do the EANOeESMO guidelines address? - Answer-✅They
address differential diagnosis, adverse effects of therapeutic measures, and supportive
or palliative care.
/.What is the primary focus of the guidelines regarding brain metastasis? - Answer-✅To
provide a comprehensive approach to diagnosis, treatment, and follow-up care.
,/.What is the importance of multidisciplinary recommendations in the EANOeESMO
guidelines? - Answer-✅They ensure a comprehensive approach to managing brain
metastasis by integrating various specialties.
/.What is the geographical scope of the institutions involved in the EANOeESMO
guidelines? - Answer-✅The institutions are located in Switzerland, the Netherlands,
France, Germany, Belgium, Austria, South Korea, and Italy.
/.What is the significance of expert opinion in the EANOeESMO guidelines? - Answer-
✅Expert opinion is crucial due to the low level of evidence from clinical trials.
/.How do the EANOeESMO guidelines benefit patients and relatives? - Answer-✅They
provide informed recommendations that can guide treatment decisions and care.
/.What is the relationship between EANO and ESMO? - Answer-✅EANO (European
Association of Neuro-Oncology) and ESMO (European Society for Medical Oncology)
collaborate to create these clinical practice guidelines.
/.What type of tumors do the EANOeESMO guidelines specifically address? - Answer-
✅Solid tumors that lead to brain metastasis.
/.What is the intended audience for the EANOeESMO guidelines? - Answer-
✅Physicians, healthcare providers, patients, and their relatives.
/.What is one challenge mentioned in the guidelines regarding treatment
recommendations? - Answer-✅The low level of evidence from clinical trials makes it
difficult to provide strong recommendations.
/.What is the primary goal of the EANOeESMO guidelines? - Answer-✅To improve the
management and outcomes of patients with brain metastasis.
/.In what context are the EANOeESMO guidelines utilized? - Answer-✅They are used
in clinical practice for managing brain metastasis.
/.What does the term 'adverse effects of therapeutic measures' refer to in the
guidelines? - Answer-✅Negative side effects resulting from treatments for brain
metastasis.
/.What is the significance of palliative care in the context of the EANOeESMO
guidelines? - Answer-✅Palliative care is essential for improving the quality of life for
patients with advanced disease.
,/.How do the EANOeESMO guidelines address the issue of evidence-based medicine?
- Answer-✅They acknowledge the reliance on expert consensus due to insufficient
clinical trial data.
/.What is the role of clinical trials in the context of the EANOeESMO guidelines? -
Answer-✅Clinical trials are important for providing evidence but are often lacking in this
area.
/.What do the current EANO-ESMO recommendations address regarding brain
metastasis? - Answer-✅They address the diagnosis and treatment of parenchymal
brain metastasis from solid cancers.
/.What types of brain metastasis are not covered by the EANO-ESMO
recommendations? - Answer-✅They do not address brain metastasis from primary
brain tumors, lymphoma, or leukemia.
/.What aspects of brain metastasis do the EANO-ESMO recommendations cover? -
Answer-✅They cover prevention, diagnosis, therapy, and follow-up.
/.Where can details on the epidemiology and pathogenesis of brain metastasis be
found? - Answer-✅In the Supplementary Material available at
10.1016/j.annonc.2021.07.016.
/.What is the typical clinical presentation timeline for brain metastasis? - Answer-✅The
clinical history is commonly short, with neurological symptoms developing within weeks.
/.What neurological symptoms can brain metastasis cause? - Answer-✅They can cause
headaches, epileptic seizures, motor deficits, personality changes, aphasia, visual
disturbances, and symptoms of raised intracranial pressure.
/.What factors influence the risk of epilepsy in patients with brain metastasis? - Answer-
✅The risk probably depends on proximity to the cortex and the presence of tumoral
hemorrhage.
/.What should be included in a neurological examination when diagnosing brain
metastasis? - Answer-✅A detailed neurological examination using a standard
evaluation form, such as that proposed by the RANO group.
/.What should trigger a neurological work-up in cancer patients? - Answer-✅New
neurological symptoms and signs.
/.What is the role of neuroimaging in the diagnosis of brain metastasis? - Answer-✅It is
used to distinguish brain metastasis from other causes of neurological morbidity.
, /.Which cancer patients are at high risk for brain metastasis and may require screening?
- Answer-✅Patients with lung cancer (especially non-squamous lung cancers), stage IV
melanoma, and metastatic HER2-positive or triple-negative breast cancer.
/.What is the preferred imaging technique for detecting brain metastasis? - Answer-
✅MRI is preferred due to its higher sensitivity compared to CT.
/.What factors influence the sensitivity of MRI for detecting brain metastasis? - Answer-
✅Field strength, contrast agent type and dose, delay between contrast administration
and data acquisition, and resolution.
/.What is the advantage of using a double-dose contrast agent in MRI? - Answer-✅It
increases imaging sensitivity but may decrease specificity.
/.What is the recommended delay between contrast agent administration and image
acquisition for optimal MRI results? - Answer-✅At least several minutes.
/.When should cranial CT be used for brain metastasis detection? - Answer-✅It should
be limited to patients with contraindications for MRI.
/.What is the common cause of rapid neurological deterioration in patients with brain
metastasis? - Answer-✅Haemorrhage from melanoma or chorionic carcinoma, or
obstructive hydrocephalus from cerebellar brain metastasis.
/.What are the potential symptoms of obstructive hydrocephalus in brain metastasis? -
Answer-✅Symptoms may include headaches and signs of raised intracranial pressure.
/.What is the significance of early diagnosis of brain metastasis in cancer patients? -
Answer-✅Early diagnosis may impact clinical decision-making and improve outcomes.
/.What is the role of the EANO Executive Board and ESMO Guidelines Committee in the
development of the guidelines? - Answer-✅They approved the guidelines developed by
the EANO and ESMO.
/.When were the EANO-ESMO guidelines approved? - Answer-✅In August 2021.
/.What are some common focal symptoms associated with brain metastasis? - Answer-
✅Focal symptoms depend on the location of the brain metastasis.
/.What is the importance of documenting neurological examinations during follow-up for
brain metastasis? - Answer-✅It helps track the progression of symptoms and the
effectiveness of treatment.
Metastasis Management Questions
And Answers
/.What do the EANOeESMO Clinical Practice Guidelines focus on? - Answer-
✅Diagnosis, treatment, and follow-up of patients with brain metastasis from solid
tumors.
/.Who are the authors of the EANOeESMO Clinical Practice Guidelines? - Answer-✅E.
Le Rhun, M. Guckenberger, M. Smits, R. Dummer, T. Bachelot, F. Sahm, N. Galldiks,
E. de Azambuja, A. S. Berghoff, P. Metellus, S. Peters, Y.-K. Hong, F. Winkler, D.
Schadendorf, M. van den Bent, J. Seoane, R. Stahel, G. Minniti, P. Wesseling, M.
Weller, and M. Preusser.
/.What is the significance of the EANOeESMO recommendations despite the low level
of evidence? - Answer-✅They serve as a valuable source of information for physicians,
healthcare providers, and informed patients and relatives.
/.What is the basis for the recommendations in the EANOeESMO guidelines? - Answer-
✅The recommendations are often based on expert opinion and consensus rather than
on evidence from informative clinical trials.
/.What are some key terms associated with the EANOeESMO guidelines? - Answer-
✅Central nervous system, cerebral, clinical practice, guideline, neurological,
recommendations.
/.When were the EANOeESMO Clinical Practice Guidelines made available online? -
Answer-✅6 August 2021.
/.What is the role of the EANO Executive Board and ESMO Guidelines Committee in the
guidelines? - Answer-✅They are responsible for the development and endorsement of
the clinical practice guidelines.
/.What types of care do the EANOeESMO guidelines address? - Answer-✅They
address differential diagnosis, adverse effects of therapeutic measures, and supportive
or palliative care.
/.What is the primary focus of the guidelines regarding brain metastasis? - Answer-✅To
provide a comprehensive approach to diagnosis, treatment, and follow-up care.
,/.What is the importance of multidisciplinary recommendations in the EANOeESMO
guidelines? - Answer-✅They ensure a comprehensive approach to managing brain
metastasis by integrating various specialties.
/.What is the geographical scope of the institutions involved in the EANOeESMO
guidelines? - Answer-✅The institutions are located in Switzerland, the Netherlands,
France, Germany, Belgium, Austria, South Korea, and Italy.
/.What is the significance of expert opinion in the EANOeESMO guidelines? - Answer-
✅Expert opinion is crucial due to the low level of evidence from clinical trials.
/.How do the EANOeESMO guidelines benefit patients and relatives? - Answer-✅They
provide informed recommendations that can guide treatment decisions and care.
/.What is the relationship between EANO and ESMO? - Answer-✅EANO (European
Association of Neuro-Oncology) and ESMO (European Society for Medical Oncology)
collaborate to create these clinical practice guidelines.
/.What type of tumors do the EANOeESMO guidelines specifically address? - Answer-
✅Solid tumors that lead to brain metastasis.
/.What is the intended audience for the EANOeESMO guidelines? - Answer-
✅Physicians, healthcare providers, patients, and their relatives.
/.What is one challenge mentioned in the guidelines regarding treatment
recommendations? - Answer-✅The low level of evidence from clinical trials makes it
difficult to provide strong recommendations.
/.What is the primary goal of the EANOeESMO guidelines? - Answer-✅To improve the
management and outcomes of patients with brain metastasis.
/.In what context are the EANOeESMO guidelines utilized? - Answer-✅They are used
in clinical practice for managing brain metastasis.
/.What does the term 'adverse effects of therapeutic measures' refer to in the
guidelines? - Answer-✅Negative side effects resulting from treatments for brain
metastasis.
/.What is the significance of palliative care in the context of the EANOeESMO
guidelines? - Answer-✅Palliative care is essential for improving the quality of life for
patients with advanced disease.
,/.How do the EANOeESMO guidelines address the issue of evidence-based medicine?
- Answer-✅They acknowledge the reliance on expert consensus due to insufficient
clinical trial data.
/.What is the role of clinical trials in the context of the EANOeESMO guidelines? -
Answer-✅Clinical trials are important for providing evidence but are often lacking in this
area.
/.What do the current EANO-ESMO recommendations address regarding brain
metastasis? - Answer-✅They address the diagnosis and treatment of parenchymal
brain metastasis from solid cancers.
/.What types of brain metastasis are not covered by the EANO-ESMO
recommendations? - Answer-✅They do not address brain metastasis from primary
brain tumors, lymphoma, or leukemia.
/.What aspects of brain metastasis do the EANO-ESMO recommendations cover? -
Answer-✅They cover prevention, diagnosis, therapy, and follow-up.
/.Where can details on the epidemiology and pathogenesis of brain metastasis be
found? - Answer-✅In the Supplementary Material available at
10.1016/j.annonc.2021.07.016.
/.What is the typical clinical presentation timeline for brain metastasis? - Answer-✅The
clinical history is commonly short, with neurological symptoms developing within weeks.
/.What neurological symptoms can brain metastasis cause? - Answer-✅They can cause
headaches, epileptic seizures, motor deficits, personality changes, aphasia, visual
disturbances, and symptoms of raised intracranial pressure.
/.What factors influence the risk of epilepsy in patients with brain metastasis? - Answer-
✅The risk probably depends on proximity to the cortex and the presence of tumoral
hemorrhage.
/.What should be included in a neurological examination when diagnosing brain
metastasis? - Answer-✅A detailed neurological examination using a standard
evaluation form, such as that proposed by the RANO group.
/.What should trigger a neurological work-up in cancer patients? - Answer-✅New
neurological symptoms and signs.
/.What is the role of neuroimaging in the diagnosis of brain metastasis? - Answer-✅It is
used to distinguish brain metastasis from other causes of neurological morbidity.
, /.Which cancer patients are at high risk for brain metastasis and may require screening?
- Answer-✅Patients with lung cancer (especially non-squamous lung cancers), stage IV
melanoma, and metastatic HER2-positive or triple-negative breast cancer.
/.What is the preferred imaging technique for detecting brain metastasis? - Answer-
✅MRI is preferred due to its higher sensitivity compared to CT.
/.What factors influence the sensitivity of MRI for detecting brain metastasis? - Answer-
✅Field strength, contrast agent type and dose, delay between contrast administration
and data acquisition, and resolution.
/.What is the advantage of using a double-dose contrast agent in MRI? - Answer-✅It
increases imaging sensitivity but may decrease specificity.
/.What is the recommended delay between contrast agent administration and image
acquisition for optimal MRI results? - Answer-✅At least several minutes.
/.When should cranial CT be used for brain metastasis detection? - Answer-✅It should
be limited to patients with contraindications for MRI.
/.What is the common cause of rapid neurological deterioration in patients with brain
metastasis? - Answer-✅Haemorrhage from melanoma or chorionic carcinoma, or
obstructive hydrocephalus from cerebellar brain metastasis.
/.What are the potential symptoms of obstructive hydrocephalus in brain metastasis? -
Answer-✅Symptoms may include headaches and signs of raised intracranial pressure.
/.What is the significance of early diagnosis of brain metastasis in cancer patients? -
Answer-✅Early diagnosis may impact clinical decision-making and improve outcomes.
/.What is the role of the EANO Executive Board and ESMO Guidelines Committee in the
development of the guidelines? - Answer-✅They approved the guidelines developed by
the EANO and ESMO.
/.When were the EANO-ESMO guidelines approved? - Answer-✅In August 2021.
/.What are some common focal symptoms associated with brain metastasis? - Answer-
✅Focal symptoms depend on the location of the brain metastasis.
/.What is the importance of documenting neurological examinations during follow-up for
brain metastasis? - Answer-✅It helps track the progression of symptoms and the
effectiveness of treatment.
